Influenza neuraminidase
- PMID: 22085243
- PMCID: PMC3290697
- DOI: 10.1111/j.1750-2659.2011.00304.x
Influenza neuraminidase
Abstract
Influenza neuraminidase is the target of two licensed antivirals that have been very successful, with several more in development. However, neuraminidase has been largely ignored as a vaccine target despite evidence that inclusion of neuraminidase in the subunit vaccine gives increased protection. This article describes current knowledge on the structure, enzyme activity, and antigenic significance of neuraminidase.
© 2011 Blackwell Publishing Ltd.
Figures
References
-
- Palese P, Schulman J. Inhibitors of viral neuraminidase as potential antiviral drugs; in: Oxford JS, (ed.): Chemoprophylaxis and Virus Infection of the Upper Respiratory Tract. Boca Raton, FL: CRC Press, 1977; 189–205.
-
- Colman PM. New antivirals and drug resistance. Annu Rev Biochem 2009; 78:95–118. - PubMed
-
- Saladino R, Barontini M, Crucianelli M et al. Current advances in anti‐influenza therapy. Curr Med Chem 2010; 17:2101–2140. - PubMed
-
- Kirchmair J, Distinto S, Liedl KR et al. Development of anti‐viral agents using molecular modeling and virtual screening techniques. Infect Disord Drug Targets 2011; 11:64–93. - PubMed
-
- Mitrasinovic PM. Advances in the structure‐based design of the influenza A neuraminidase inhibitors. Curr Drug Targets 2010; 11:315–326. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
